Biocon Limited has formally notified stock exchanges about the record date for the buyback of its commercial paper issue worth Rs. 1,800 crore. The company has set January 29, 2026 as the record date, with the redemption scheduled for the following day.

Commercial Paper Details

The commercial paper buyback involves a substantial issue that demonstrates the company's debt management activities. The following table outlines the key parameters of this commercial paper:

Regulatory Communication

Biocon submitted this intimation to both major stock exchanges through a formal communication dated January 28, 2026. The notification was addressed to BSE Limited and National Stock Exchange of India Limited, ensuring compliance with regulatory requirements for commercial paper transactions.

This announcement represents a follow-up to the company's earlier communication dated December 24, 2025, where Biocon had initially intimated the record date and maturity date for this particular commercial paper bearing ISIN INE376G14040.

Corporate Compliance

The notification was signed by Rajesh U. Shanoy, Company Secretary and Compliance Officer, maintaining the company's adherence to corporate governance standards. The communication was also copied to National Securities Depository Limited and KFin Technologies Limited, the company's registrar and transfer agent, ensuring all relevant stakeholders are informed about the buyback timeline.

Biocon Limited has notified stock exchanges about receiving a Voluntary Action Indicated (VAI) status from the U.S. Food and Drug Administration for one of its API manufacturing facilities. The pharmaceutical company disclosed this regulatory development through official communications to both major Indian stock exchanges on January 28, 2026.

Facility Details and Inspection Timeline

The VAI status pertains to Biocon's API facility situated at a specific location in Andhra Pradesh. The US FDA conducted its inspection over a five-day period, providing a comprehensive assessment of the manufacturing operations.

Regulatory Compliance and Disclosure

Biocon has fulfilled its disclosure obligations by informing both BSE Limited and National Stock Exchange of India Limited about this regulatory development. The company's notification was signed by Rajesh Umakant Shanoy, Company Secretary and Compliance Officer, ensuring proper corporate governance protocols were followed.

The pharmaceutical company has also made this information available on its official website at www.biocon.com , providing transparency to all stakeholders. This disclosure falls under Regulation 30 requirements, which mandate listed companies to inform exchanges about material events that could impact investor decisions.

Communication to Stock Exchanges

The formal notification was addressed to both major Indian stock exchanges with specific reference numbers for tracking purposes.

The company has requested both exchanges to acknowledge receipt of this notification and maintain it on record as part of standard compliance procedures.